Brown, Lisle/Cummings’s Acadia Pharmaceuticals ACAD Stock Holding History

Brown, Lisle/Cummings’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.7K	Hold	500	–	–	﹤0.01%	580
2026 Q1	$11.1K	Hold	500	–	–	﹤0.01%	556
2025 Q4	$13.4K	Hold	500	–	–	﹤0.01%	471
2025 Q3	$10.7K	Hold	500	–	–	﹤0.01%	496
2025 Q2	$10.8K	Hold	500	–	–	﹤0.01%	496
2025 Q1	$8.3K	Hold	500	–	–	﹤0.01%	513
2024 Q4	$9.18K	Buy	500 +250	+100%	+$4.04K	﹤0.01%	494
2024 Q3	$3.85K	Hold	250	–	–	﹤0.01%	533
2024 Q2	$4.06K	Buy	+250	New	+$4.04K	﹤0.01%	521

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Brown, Lisle/Cummings's ACAD Position: Q2 2026 in Review

Brown, Lisle/Cummings held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 500 shares worth $12.7K. The position accounts for ﹤0.01% of the portfolio, ranked #580.

Brown, Lisle/Cummings first reported a position in ACAD in Q2 2024 and has held it in 9 quarters since. The position peaked at $13.4K in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Brown, Lisle/Cummings held 500 shares of Acadia Pharmaceuticals worth $12.7K as of Q2 2026.
Brown, Lisle/Cummings left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #580 holding.
Brown, Lisle/Cummings first reported a position in Acadia Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Brown, Lisle/Cummings's Acadia Pharmaceuticals position peaked at $13.4K in Q4 2025.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.